Abstract
Background: Amyloid β40 (Aβ40) is the most abundant Aβ peptide in the brain. The cerebrospinal fluid (CSF) level of Aβ40 might therefore be considered to most closely reflect the total Aβ load in the brain. Both in Alzheimers disease (AD) and in normal aging the Aβ load in the brain has a large inter-individual variability. Relating Aβ42 to Aβ40 levels might consequently provide a more valid measure for reflecting the change in Aβ metabolism in dementia patients than the CSF Aβ42 concentrations alone. This measure may also improve differential diagnosis between AD and other dementia syndromes, such as vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). Objective: To investigate the diagnostic value of the CSF Aβ42/Aβ40 ratio in differentiating AD from controls, VaD, DLB and FTD. Methods: We analysed the CSF Aβ42/Aβ40 ratio, phosphorylated tau181 and total tau in 69 patients with AD, 26 patients with VaD, 16 patients with DLB, 27 patients with FTD, and 47 controls. Results: Mean Aβ40 levels were 2850 pg/ml in VaD and 2830 pg/ml in DLB patients, both significantly lower than in AD patients (3698 pg/ml; p < 0.01). Aβ40 levels in AD patients were not significantly different from those in controls (4035 pg/ml; p=0.384). The Aβ42/Aβ40 ratio was significantly lower in AD patients than in all other groups (p < 0.001, ANCOVA). Differentiating AD from VaD, DLB and non-AD dementia improved when the Aβ42/Aβ40 ratio was used instead of Aβ42 concentrations alone (p < 0.01) The Aβ42/Aβ40 ratio performed equally well as the combination of Aβ42, phosphorylated tau181 and total tau in differentiating AD from FTD and non-AD dementia. The diagnostic performance of the latter combination was not improved when the Aβ42/Aβ40 ratio was used instead of Aβ42 alone. Conclusion: The CSF Aβ42/Aβ40 ratio improves differentiation of AD patients from VaD, DLB and non-AD dementia patients, when compared to Aβ42 alone, and is a more easily interpretable alternative to the combination of Aβ42, p-tau and t-tau when differentiating AD from either FTD or non-AD dementia.
Keywords: Abeta40 protein, Aβ42/Aβ40 ratio, Alzheimer's disease, vascular dementia, dementia with Lewy bodies
Current Alzheimer Research
Title: The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimers Disease from Non-Alzheimers Dementia
Volume: 7 Issue: 5
Author(s): P.E. Spies, D. Slats, J.M.C. Sjogren, B.P.H. Kremer, F.R.J. Verhey, M.G.M. Olde Rikkert and M.M. Verbeek
Affiliation:
Keywords: Abeta40 protein, Aβ42/Aβ40 ratio, Alzheimer's disease, vascular dementia, dementia with Lewy bodies
Abstract: Background: Amyloid β40 (Aβ40) is the most abundant Aβ peptide in the brain. The cerebrospinal fluid (CSF) level of Aβ40 might therefore be considered to most closely reflect the total Aβ load in the brain. Both in Alzheimers disease (AD) and in normal aging the Aβ load in the brain has a large inter-individual variability. Relating Aβ42 to Aβ40 levels might consequently provide a more valid measure for reflecting the change in Aβ metabolism in dementia patients than the CSF Aβ42 concentrations alone. This measure may also improve differential diagnosis between AD and other dementia syndromes, such as vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). Objective: To investigate the diagnostic value of the CSF Aβ42/Aβ40 ratio in differentiating AD from controls, VaD, DLB and FTD. Methods: We analysed the CSF Aβ42/Aβ40 ratio, phosphorylated tau181 and total tau in 69 patients with AD, 26 patients with VaD, 16 patients with DLB, 27 patients with FTD, and 47 controls. Results: Mean Aβ40 levels were 2850 pg/ml in VaD and 2830 pg/ml in DLB patients, both significantly lower than in AD patients (3698 pg/ml; p < 0.01). Aβ40 levels in AD patients were not significantly different from those in controls (4035 pg/ml; p=0.384). The Aβ42/Aβ40 ratio was significantly lower in AD patients than in all other groups (p < 0.001, ANCOVA). Differentiating AD from VaD, DLB and non-AD dementia improved when the Aβ42/Aβ40 ratio was used instead of Aβ42 concentrations alone (p < 0.01) The Aβ42/Aβ40 ratio performed equally well as the combination of Aβ42, phosphorylated tau181 and total tau in differentiating AD from FTD and non-AD dementia. The diagnostic performance of the latter combination was not improved when the Aβ42/Aβ40 ratio was used instead of Aβ42 alone. Conclusion: The CSF Aβ42/Aβ40 ratio improves differentiation of AD patients from VaD, DLB and non-AD dementia patients, when compared to Aβ42 alone, and is a more easily interpretable alternative to the combination of Aβ42, p-tau and t-tau when differentiating AD from either FTD or non-AD dementia.
Export Options
About this article
Cite this article as:
Spies P.E., Slats D., Sjogren J.M.C., Kremer B.P.H., Verhey F.R.J., Olde Rikkert M.G.M. and Verbeek M.M., The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimers Disease from Non-Alzheimers Dementia, Current Alzheimer Research 2010; 7 (5) . https://dx.doi.org/10.2174/156720510791383796
DOI https://dx.doi.org/10.2174/156720510791383796 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index to Volume 4
Current Medicinal Chemistry - Central Nervous System Agents Brain Network Connectivity Mediates Education-related Cognitive Performance in Healthy Elderly Adults
Current Alzheimer Research Crocetin Attenuates Spatial Learning Dysfunction and Hippocampal Injury in a Model of Vascular Dementia
Current Neurovascular Research Anti-inflammatory Effects of Dietary Antioxidants
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Commentary Research Highlights (Amyloid and Alzheimer's Disease: Easing the Load)
CNS & Neurological Disorders - Drug Targets Targeting Microglial Polarization to Improve TBI Outcomes
CNS & Neurological Disorders - Drug Targets Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment
Current Pharmaceutical Design Development of a Nasal Donepezil-loaded Microemulsion for the Treatment of Alzheimer’s Disease: in vitro and ex vivo Characterization
CNS & Neurological Disorders - Drug Targets Future Targeted Disease Modifying Drugs for Alzheimer's Disease
Recent Patents on CNS Drug Discovery (Discontinued) Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease
Current Neuropharmacology A Predictive Model of the Prevalence of Delirium in Elderly Subjects Admitted to Nursing Homes
Endocrine, Metabolic & Immune Disorders - Drug Targets Niacin Status, NAD Distribution and ADP-Ribose Metabolism
Current Pharmaceutical Design Renin-Angiotensin System: Role in Cerebrovascular, Neurodegenerative and Psychiatric Disease
Protein & Peptide Letters Triggering Receptor Expressed on Myeloid Cells (TREM) Family and the Application of Its Antagonists
Recent Patents on Anti-Infective Drug Discovery In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Synthesis of Highly Functionalised Dispiropyrrolidine Derivatives as Novel Acetylcholinesterase Inhibitors
Letters in Drug Design & Discovery The Peripheral Anionic Site of Acetylcholinesterase: Structure, Functions and Potential Role in Rational Drug Design
Current Pharmaceutical Design Significance of High Levels of Endogenous Melatonin in Mammalian Cerebrospinal Fluid and in the Central Nervous System
Current Neuropharmacology Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Hypometabolism in Brain of Cognitively Normal Patients with Depressive Symptoms is Accompanied by Atrophy-Related Partial Volume Effects
Current Alzheimer Research